Palvella Therapeutics (PVLA) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 98.0% versus a loss of 14.4%. Over five years, VRDN leads with a +9.3% price change compared with -63.6% for PVLA. Viridian Therapeutics is the larger company by market cap ($2.11 billion vs $2.00 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | VRDN |
|---|---|---|
| Share price | $138.77 | $18.66 |
| Market cap | $2.00B | $2.11B |
| 1-day change | +5.66% | +1.74% |
| YTD return | +32.58% | -40.04% |
| 1-year return | +97.99% | -14.44% |
| 5-year return | -63.60% | +9.31% |
| EPS (TTM) | $-4.85 | $-3.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | $-41.72M | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $161.38 | $34.29 |
| 52-week low | $65.93 | $13.18 |
| Distance from 52-week high | -14.01% | -45.58% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +66.12% | +96.95% |
| Average volume | 211.36K | 1.71M |
| Shares outstanding | 14.41M | 113.29M |
| Employees | 29 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed VRDN by 112.4 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
PVLA vs VRDN FAQ
Which is bigger, Palvella Therapeutics or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $2.11B compared with $2.00B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, PVLA or VRDN?
PVLA returned +97.99% over the past 12 months, compared with -14.44% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.